105 pharmacies were bought by the people's big pharmacies.

According to the semi-annual report, during the reporting period, The People's Big Pharmacy and its subsidiaries completed a total of eight mergers and acquisitions and bought 105 pharmacies.
As follows: In January 2020, the Company entered into an acquisition agreement with Xiangxiang and Spring Pharmacy (General Partnership) and others to acquire assets and businesses related to the 26 stores under its control for a purchase price of 32.7928 million yuan (including 1.7928 million yuan), and the project was completed in March 2020.
2, 2020, the company's subsidiary Anhui People's Big Pharmacy Chain Co., Ltd. signed a business and asset acquisition agreement with Anhui Anning Big Pharmacy Chain Limited, the acquisition of 20 stores under its control related business and assets, the purchase price of 50.46 million yuan (including 2.1 million yuan), the project was completed in April 2020.
3, April 2020, Shanxi Parkson Pharmaceutical Chain Co., Ltd., a subsidiary of the Company, signed an equity acquisition agreement with Li Peng and Haoyu Trading Limited in Linyi City,000 to purchase a 51% stake in Parkson Pharmaceutical Co., Ltd. (a total of 14 stores) in Yanqu County with a transfer price of 7.6857 million yuan, and the project was completed in April 2020.
, May 2020, Nantong Puze Pharmacy Chain Co., Ltd., a subsidiary of the Company, signed an equity acquisition agreement with Chen Gang and Ji Ping to purchase an 80% stake in Nantong Integrity Pharmacy Chain Co., Ltd. (a total of 12 stores) with a transfer price of 40.92 million yuan, and the project was completed in May 2020.
May 2020, the Company signed an asset and business acquisition agreement with Lexian Grand Pharmacy in Zhangzhou City and Chi Pharmaceutical Pharmacy Co., Ltd. in Zhangzhou City to acquire assets and business related to 22 stores under its control for a purchase price of 15.8 million yuan (excluding 2.2 million yuan), and the project was completed in June 2020.
, May 2020, the Company entered into asset and business acquisition agreements with Lee Hsien-dong and Ling Jianhong to acquire assets and businesses related to 11 stores under its control for a price of 16 million yuan (excluding $2.2 million), and the project was completed in May 2020.
7, June 2020, the company's subsidiary Anhui People's Big Pharmacy Chain Co., Ltd. signed an equity acquisition agreement with Shi Min and Yang Jun, after restructuring to buy a 100% stake in Wuhu Jianjia Pharmaceutical Trading Co., Ltd., with a transfer price of 3 million yuan, the project is still in the process of delivery.
, June 2020, the Company signed an equity transfer agreement with Lin Chengxiong to purchase a 4.28% stake in Hunan WairenDa Health Industry Development Co., Ltd. at a transfer price of 84.0699 million yuan.
the project was completed in July 2020.
stores cover 130 places, in order to preempt the prescription outflow in 2020, under the impact of the new crown outbreak, "Internet plus health care" accelerated, accelerating the pace of prescription outflow.
April 10, the National Development and Reform Commission and the Central Web Office issued the "On promoting the "on the cloud with a number of wisdom" action to foster the implementation of new economic development program (Reform high-tech (2020) No. 552) proposed to explore in the field of health and health care to promote the Internet medical insurance first consultation system and appointment of the three-diagnosis system.
May 21, the General Office of the National Health and Health Commission on the further improvement of the appointment system to strengthen the construction of smart hospitals notice (National Health Service Medical Letter (2020) No. 405), requiring hospitals to open offline services, online to carry out some common diseases, chronic diseases, and actively join forces with social forces to carry out drug distribution and other services.
the acceleration of medical insurance electronic vouchers, the promotion of prescription sharing platform, the introduction of volume purchase and other policies to further promote the outflow of prescriptions.
According to the semi-annual report, during the reporting period, the marketing network of large pharmacies (including franchise business) has covered 22 provincial markets and more than 130 cities at or above the local level, becoming one of the leading pharmaceutical retail enterprises in the country.
people's big pharmacies in Hunan, Jiangsu, Anhui, Shaanxi, Guangxi, Tianjin, Gansu, Inner Mongolia and other 11 provinces market share leading, and continue to work deep to steadily enhance the leading position.
At present, the proportion of people's large pharmacy direct stores health insurance stores 89.83 percent, hospital side stores accounted for 11.05 percent, DTP pharmacies 137, special consultations 340, in order to undertake prescription drug outflow accounted for the first opportunity.
industry development, or ushered in 6 changes In addition, the semi-annual report according to the current market situation, combed the cyclical characteristics of the industry, as follows: 1, the retail terminal drug market is steadily rising the size of the pharmaceutical retail industry is an important part of the pharmaceutical circulation industry, and retail pharmacies are pharmaceutical manufacturers to sell products to consumers one of the important terminal channels.
With the introduction of various national medical reform and health industry policies, the "drug separation" reform is becoming more and more obvious, coupled with the promotion of prescription outflow policy, China's retail terminal drug market size and share has steadily increased.
2019, china's drug retail market sales amounted to 466.1 billion yuan, up 9.85% YoY and up 0.97 percentage points.
2, pharmacy chain rate to further enhance the retail chain rate, is conducive to enhance market concentration and corporate market reputation, is conducive to reducing government regulatory costs and business operating costs.
According to the National Drug Circulation Industry Development Plan (2016-2020), the annual sales of the top 100 pharmaceutical retail enterprises will account for more than 40% of the total drug retail market by 2020, and the retail chain rate of pharmaceuticals will reach more than 50%.
with the improvement of the level of development of the industry and the government support policies continue to be introduced, the channel control of chain pharmacies will be further enhanced, the number of chain stores will increase accordingly, the retail pharmacy chain rate will be further increased.
3, industry competition to promote horizontal integration trend With the increasingly strict national regulatory policy, single drugstores and small and medium-sized pharmacy chain enterprises continue to increase the cost of hardware and software input, labor costs, rent costs and the lack of purchasing bargaining power, single pharmacies and small and medium-sized pharmacy chain enterprises operating pressure is increasing.
Large retail pharmacy chain enterprises have a sound procurement, logistics, sales system, forming a strong scale advantage and brand influence, through chaining, scale to improve competitive strength, through listing financing, mergers and reorganization and other ways of horizontal integration, to achieve large-scale, intensive chain management.
4, pharmaceutical e-commerce market initially formed, in a rapid growth stage With the rapid development of the domestic e-commerce industry, China's pharmaceutical e-commerce market has been initially formed.
The future market has broad prospects for development: on the one hand, industry regulatory policies have created a good regulatory environment for the development of pharmaceutical e-commerce, on the other hand, the rapid development of Internet information technology, including drug information release, online transactions, drug tracking, etc., also provides a means of technological realization for online drug transactions.
with the gradual implementation of "drug separation", "prescription outflow", the future of the release of prescription drugs sold online, have created new growth points for pharmaceutical e-commerce.
5. The competition of retail pharmacies presents the characteristics of diversification and differentiation With the continuous development and maturity of China's retail pharmacy industry, the competition between enterprises has gradually changed from price competition to diversified and differentiated competition, mainly reflected in the continuous upgrading of the commodity system and diversified industry innovation.
Retail pharmacies on the one hand in the operation of the rising commodity system, through increased professional marketing of prescription drugs, disease analysis and other means to improve commodity marketing, in the commodity portfolio to over-the-counter drugs and non-drug commodities expansion;
6, pharmacies to further improve the professional service capacity In recent years, the public hospital reform in full swing and health insurance charges and other supporting policies have been introduced, "medical separation" reform trend is becoming increasingly obvious.
retail pharmacies have gradually developed from a single drug sales channel to provide drugs, medical devices, health care products and other health products and services an important carrier.
ability to specialize in services has become one of the competitive advantages of retail pharmacies.
Retail pharmacies pay more and more attention to the training of professional and technical personnel, customer experience as the center, big data-driven, the use of "new retail" technology to provide customers with specialized services, diagnosis and treatment, drug purchase, health management and other organic combination, full-time to provide customers with family health solutions, with the continuous expansion of our country's professional pharmacists and retail pharmacies to professional service level, China's retail pharmacy industry will further improve the level of specialized services.
.